But few people get that support especially those prescribed GLP-1s from their primary care physicians (PCPs)
GLP-1RAs and cardiovascular-renal outcomes in type 2 diabetes systematic review (2021) highlights significant reductions in cardiovascular events, kidney disease progression, and mortality among GLP-1 users
What we CAN do We have options and a majority of the GLP-1 and GIP products will now be offered at less of a cost to you and in a more convenient oral form
Clinical trials have shown that semaglutide and liraglutide are generally well tolerated, with gastrointestinal disorders being the most commonly reported AEs, including nausea, diarrhea, vomiting, and constipation, leading to dose reduction or temporary treatment interruption in 12.5% of study participants [40,41,42]
Treatment with GLP-1RA downregulates NF-B activation in hepatic tissue, thereby leading to decreased transcription of cytokines and chemokines that sustain inflammation (23, 24)
%20(1).png)
